Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefaclor revisited.

B R Meyers1

  • 1Division of Infectious Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA.

Clinical Therapeutics
|April 1, 2000
PubMed
Summary
This summary is machine-generated.

Cefaclor, an effective antibiotic for respiratory infections, offers good tolerability and efficacy. Extended-release cefaclor provides comparable results with improved dosing compliance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens.

Transplantation·2000
Same author

Study of a needleless intermittent intravenous-access system for peripheral infusions: analysis of staff, patient, and institutional outcomes.

Infection control and hospital epidemiology·1998
Same author

Infectious ocular complications in orthotopic liver transplant patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997
Same author

Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1996
Same author

High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·1995
Same author

Tuberculosis in liver transplant patients.

Transplantation·1994

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Respiratory Medicine

Background:

  • Cefaclor has demonstrated efficacy in managing respiratory tract infections since 1979.
  • Key factors include molecular stability, broad-spectrum activity, rapid absorption, high bioavailability, and good respiratory tissue penetration.
  • Despite widespread use, cefaclor remains competitive against newer antibiotics for respiratory infections.

Purpose of the Study:

  • To outline the rationale for selecting cefaclor in treating respiratory tract infections.
  • To evaluate the efficacy and tolerability of extended-release cefaclor formulations.

Main Methods:

  • A MEDLINE search was conducted to review adverse effects and drug interactions.
  • Clinical trial data were analyzed to compare extended-release and immediate-release cefaclor formulations.

Related Experiment Videos

Main Results:

  • Adverse effects associated with cefaclor are typically minor and transient.
  • Drug-drug interactions involving cefaclor are infrequent.
  • Extended-release cefaclor (375mg/500mg BID) shows efficacy and tolerability comparable to immediate-release cefaclor (250mg TID).

Conclusions:

  • Extended-release cefaclor offers comparable efficacy and tolerability to immediate-release cefaclor.
  • The twice-daily (BID) dosing of extended-release cefaclor is expected to enhance patient compliance.